Renee Lacadie, APRN
Psychiatric/Mental Health · Norwich, CTNPI 1265818355
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,175 of the $5,084 with a category attached, or 82.1%. 20 manufacturers reported payments, led by Johnson & Johnson at 25.3% of the total. Reporting peaked in 2022 at $2,444 and has fallen 99.4% since, to $13 in 2025. Among psychiatric/mental health clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 226 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AbbVie$855
- Lundbeck LLC$667
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$507
- Teva Pharmaceuticals USA, Inc.$275
- Otsuka America Pharmaceutical, Inc.$267
- plus $1K from 14 others
What the payments were for
- Travel & lodging$87917%
- Food & beverage$4,17582%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 16 | $1,286 |
| AbbVie | 67 | $855 |
| Lundbeck LLC | 30 | $667 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $507 |
| Teva Pharmaceuticals USA, Inc. | 14 | $275 |
| Otsuka America Pharmaceutical, Inc. | 13 | $267 |
| Neurocrine Biosciences, Inc. | 11 | $241 |
| Vanda Pharmaceuticals Inc. | 8 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $170 |
| Supernus Pharmaceuticals, Inc. | 8 | $166 |
| Alkermes, Inc. | 6 | $124 |
| Sunovion Pharmaceuticals Inc. | 3 | $74 |
| Corium, LLC | 4 | $69 |
| Axsome Therapeutics, Inc. | 3 | $62 |
| Merck | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Tris Pharma Inc | 1 | $15 |
| Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$1,003
How this compares
$5,084 in reported general payments places this provider in the 90th percentile of 679 psychiatric/mental health providers in Connecticut.
See all psychiatric/mental health providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 29 | $43,173 |
| Invega SustennaPaliperidone Palmitate | 15 | $38,108 |
| RexultiBrexpiprazole | 20 | $26,973 |
| CaplytaLumateperone Tosylate | 14 | $25,766 |
| TrintellixVortioxetine Hydrobromide | 22 | $15,157 |
| VyvanseLisdexamfetamine Dimesylate | 39 | $14,887 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $13,414 |
| Lurasidone Hcl | 15 | $5,253 |
| Vilazodone Hcl | 31 | $3,249 |
| Adderall XrDextroamphetamine/Amphetamine | 13 | $2,933 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 39 | $2,135 |
| Acamprosate Calcium | 13 | $2,014 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 62 | $1,522 |
| Gabapentin | 104 | $1,400 |
| Dextroamphetamine Sulfate | 18 | $1,174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $855 | $43,17329 claims |
| Johnson & JohnsonInvega Sustenna | $1,286 | $38,10815 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $170 | $30,04461 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $267 | $26,97320 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $507 | $25,76614 claims |
| Axsome Therapeutics, Inc.Auvelity | $62 | $13,41413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 679 psychiatric/mental health providers in Connecticut.
Other psychiatric/mental health in Norwich
- Hui HuNorwich$19K
- John KempNorwich$9K
- Cristina MeehanNew Britain$224K
- Samantha MrazBridgeport$87K
- Philip FrickManchester$31K
- Gia SantoroWest Haven$25K
- Donna DraperDanbury$19K
- Zahida SairitupaDanbury$19K
- Patrick GagnonMilford$15K
- Max Greger-MoserNew Haven$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.